{"count": 2, "results": [{"_id": "39623260", "pmid": 39623260, "title": "[Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study].", "journal": "Nan Fang Yi Ke Da Xue Xue Bao", "authors": ["Wang Y", "Lai T", "Chu D", "Bai J", "Yan S", "Qin H", "Guo R"], "date": "2024-11-20T00:00:00Z", "doi": "10.12122/j.issn.1673-4254.2024.11.01", "meta_date_publication": "2024 Nov 20", "meta_volume": "44", "meta_issue": "11", "meta_pages": "2055-2062", "score": 50257.785, "text_hl": "METHODS: Sixty @SPECIES_9606 @@@patients@@@ (aged 20-42 years) with @DISEASE_Endometrial_Hyperplasia @DISEASE_MESH:D004714 @@@AEH@@@ and/or grade 1 @<m>DISEASE_Familial_cylindromatosis</m> @DISEASE_MESH:C536611 @@@EAC@@@ limited to the endometrium were enrolled prospectively and randomized into two groups (n=30) to receive oral @CHEMICAL_Medroxyprogesterone_Acetate @CHEMICAL_MESH:D017258 @@@MA@@@ treatment at the daily dose of 160 mg (control) or @CHEMICAL_Medroxyprogesterone_Acetate @CHEMICAL_MESH:D017258 @@@MA@@@ plus oral @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ (850 mg, twice a day) for at least 6 months. ", "citations": {"NLM": "Wang Y, Lai T, Chu D, Bai J, Yan S, Qin H, Guo R. [Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study]. Nan Fang Yi Ke Da Xue Xue Bao. 2024 Nov 20;44(11):2055-2062. PMID: 39623260", "BibTeX": "@article{39623260, title={[Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study].}, author={Wang Y and Lai T and Chu D and Bai J and Yan S and Qin H and Guo R}, journal={Nan Fang Yi Ke Da Xue Xue Bao}, volume={44}, number={11}, pages={2055-2062}}"}}, {"_id": "28088698", "pmid": 28088698, "title": "Metformin enhancing the antitumor efficacy of carboplatin against Ehrlich solid carcinoma grown in diabetic mice: Effect on IGF-1 and tumoral expression of IGF-1 receptors.", "journal": "Int Immunopharmacol", "authors": ["Abo-Elmatty DM", "Ahmed EA", "Tawfik MK", "Helmy SA"], "date": "2017-03-01T00:00:00Z", "doi": "10.1016/j.intimp.2017.01.002", "meta_date_publication": "2017 Mar", "meta_volume": "44", "meta_issue": "", "meta_pages": "72-86", "score": 50048.418, "text_hl": "Therefore, the study aimed to evaluate the in vivo antitumor activity of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ against solid @<m>DISEASE_Familial_cylindromatosis</m> @DISEASE_MESH:C536611 @@@EAC tumor@@@ growth in female @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @SPECIES_10090 @@@mice@@@ and its potential pro-apoptotic and anti-proliferative effects with clarification of its inconclusive biological mechanisms. ", "citations": {"NLM": "Abo-Elmatty DM, Ahmed EA, Tawfik MK, Helmy SA. Metformin enhancing the antitumor efficacy of carboplatin against Ehrlich solid carcinoma grown in diabetic mice: Effect on IGF-1 and tumoral expression of IGF-1 receptors. Int Immunopharmacol. 2017 Mar;44():72-86. PMID: 28088698", "BibTeX": "@article{28088698, title={Metformin enhancing the antitumor efficacy of carboplatin against Ehrlich solid carcinoma grown in diabetic mice: Effect on IGF-1 and tumoral expression of IGF-1 receptors.}, author={Abo-Elmatty DM and Ahmed EA and Tawfik MK and Helmy SA}, journal={Int Immunopharmacol}, volume={44}, pages={72-86}}"}}]}